Titan Pharmaceuticals
From Infogalactic: the planetary knowledge core
| Titan Pharmaceuticals | |
| Public | |
| Traded as | NASDAQ: TTNP |
| Industry | Pharmaceuticals |
| Headquarters | California |
|
Key people
|
Sunil Bhonsle |
|
Number of employees
|
13 (June 2015) |
| Website | www.titanpharm.com |
Titan Pharmaceuticals, Inc. is a California biopharmaceutical company developing proprietary therapeutics primarily for the treatment of central nervous system ("CNS") disorders.[citation needed]
Titan's principal asset[citation needed] is Probuphine,[1] a slow-release implant formulation of buprenorphine hydrochloride (“buprenorphine”)[2] for the treatment of opioid addiction or chronic pain. Template:As of 2015, it was in phase 3 trials.[3]
References
- ↑ Probuphine®
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
External links
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
